With respect to mutational status, some studies indicate that cancer cells harboring KRAS-activating mutations are vulnerable to K-RAS-TBK1 synthetic lethality, specifically when combined with ERK-MAPK inhibitors [9, 16, 18]. The gene discussed is KRAS; the disease is cancer.